Skip to content

Zymeworks ZYME Deferred Revenue

Deferred Revenue at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$274K-4.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$7.74M-58.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$6.6M-35.6%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$18.75M-38.7%
Septerna, Inc. logo
Septerna, Inc.SEPN
$59.76M
TG Therapeutics logo
TG TherapeuticsTGTX
$6.86M+4.0%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's deferred revenue?
Zymeworks (ZYME) reported deferred revenue of $2.08M in Q1 2026.
How has Zymeworks's deferred revenue changed year-over-year?
Zymeworks's deferred revenue decreased by 91.2% year-over-year, from $23.5M to $2.08M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.